Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,008
datasets available to search
ShareScore release 0.9.0
Dataset results
4,008 results for “Heart failure”
Dataset from: "Prognostic Value of Dynamic Changes in Pulmonary Congestion During Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction"
<p>BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF) typically develop dyspnea and<br> pulmonary congestion upon exercise. Lung ultrasound is a simple diagnostic tool, providing semiquantitative assessment<br> of extravascular lung water through B-lines. It has been shown that patients with HFpEF develop B-lines upon submaximal<br> exercise stress echocardiography; however, whether exercise-induced pulmonary congestion carries prognostic implications<br> is unknown. This study aimed at evaluating the prognostic value of B-line assessment during exercise in patients with HFpEF.<br> METHODS: Sixty-one New York Heart Association class I to II patients with HFpEF underwent standard echocardiography,<br> lung ultrasound (28-scanning point method), and BNP (B-type natriuretic peptide) assessment during supine exercise<br> echocardiography (baseline and peak exercise). The primary end point was a composite of cardiovascular death or HF<br> hospitalization at 1 year.<br> RESULTS: B-lines, E/e′, and BNP significantly increased during exercise (P<0.001 for all). By multivariable analysis, both peak<br> (hazard ratio, 1.50 [95% CI, 1.21–1.85], P<0.001), and change (hazard ratio 1.34 [95% CI, 1.12–1.62], P=0.002) B-lines<br> were retained as independent predictors of outcome (hazard ratios per 1 B-line increment), along with BNP and E/e′ ratio.<br> Importantly, adding peak B-line on top of a clinical model significantly improved prognostic accuracy (C-index increase, 0.157<br> [0.056–0.258], P=0.002) and net reclassification (continuous net reclassification improvement, 0.51 [0.09–0.74], P=0.016),<br> with similar results for B-line change.<br> CONCLUSIONS: Detection of exercise-induced pulmonary congestion by lung ultrasound is an independent predictor of outcome<br> in patients with HFpEF; its use may help refining the routine risk stratification of these patients on top of well-established<br> clinical variables.</p>
Dataset related to the article "Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan"
<p>This record contains raw data related to the article "Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan".</p> <p>Abstract: In terms of sacubitril/valsartan (S/V)-induced changes in heart failure with reduced ejection fraction (HFrEF) via three-dimensional (3D) transthoracic echocardiography (TTE) and S/V effects based on HF aetiology, data are lacking. We prospectively enrolled 51 HFrEF patients (24 ischaemic, 27 non-ischaemic). At baseline and at 6-month follow-up (6MFU) after S/V treatment<br> optimisation, we assessed the N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac remodelling by two-dimensional (2D) and 3DTTE. In non-ischaemic patients, 2D and 3DTTE showed an improvement in left ventricular (LV) size and biventricular function at 6MFU vs. baseline: 3D-LV end-diastolic volume (EDV) 103 ± 30 vs. 125 ± 32 mL/m2 (p < 0.05), 3D-LV ejection<br> fraction (EF) 40 ± 9 vs. 32 ± 5% (p < 0.05), right ventricular (RV) 3D-EF 48.4 ± 6.5 vs. 44.3 ± 7.5% (p < 0.05); only the 3D method detected RV size reduction: 3D-RVEDV 63 ± 27 vs. 71 ± 30 mL/m2 (p < 0.05). In ischaemic patients, only 3DTTE showed biventricular size and LV function improvement: 3D-LVEDV 112 ± 29 vs. 121 ± 27 mL/m2 (p < 0.05), 3D-LVEF 35 ± 6 vs. 32 ± 5% (p < 0.05), 3D-RVEDV 57 ± 11 vs. 63 ± 14 mL/m2 (p < 0.05); RV function did not ameliorate. In both ischaemic and nonischaemic<br> patients, diastolic function and NT-proBNP significantly improved. In HFrEF patients treated with S/V, 3DTTE helps to ascertain subtle changes in heart chambers’ size and function, which have a major impact on HFrEF prognosis. S/V has significantly different effects on LV function in non-ischaemic vs. ischaemic patients.</p>
Dataset related to the publication Rovai S, Contini M, Sciomer S, Vignati C, Agostoni P. The double anaerobic threshold in heart failure. Int J Cardiol. 2022;353:68-70.
<p><strong>Background: </strong>Cardiopulmonary exercise test (CPET) has an important role in assessing heart failure (HF) patients. Among CPET parameters, a pivotal role is attributed to the anaerobic threshold (AT), normally determined by V-slope, ventilatory equivalent and end-tidal methods. In about 10% of healthy subjects, a lack of concordance between these methods has been reported. This event was named double AT (DT). We hypothesized that DT was due to a delay in chemoreflex response.</p> <p><strong>Methods: </strong>We reanalyzed CPET data of two cross-over studies in which we compared CPET in stable HF patients treated for two months with bisoprolol and carvedilol. In chronic HF, carvedilol has a greater sympathetic inhibition than bisoprolol, as shown by a lower chemoreflex response.</p> <p><strong>Results: </strong>In 87 patients, we identified DT in 46% and 66% of cases during bisoprolol and carvedilol treatment, respectively (p < 0.01). Compared with bisoprolol, carvedilol treatment was associated to a lower peak oxygen uptake (from 17.4 ± 4.3 to 16.4 ± 4.1 mL/min/kg) and oxygen pulse (from 11.8 ± 2.9 to 11.1 ± 2.9 mL/min/kg) suggestive of lower peak cardiac output.</p> <p><strong>Conclusions: </strong>DT is frequent in HF and more often with carvedilol than bisoprolol treatment, may be due to a greater inhibition of sympathetic tone and prolonged circulatory time. These findings open an unexplored research field.</p>
Dtaset related to the article The double anaerobic threshold in heart failure: MECKI score database overview. ESC Heart Fail. 2022;9:2119-2124.
<p> </p> <p><strong>Aims: </strong>In heart failure (HF), anaerobic threshold (AT) may be indeterminable but its value held a relevant prognostic role. AT is evaluated joining three methods: V-slope, ventilatory equivalent, and end-tidal methods. The possible non-concordance between the V-slope (met AT) and the other two methods (vent AT) has been highlighted in healthy individuals and named double threshold (DT).</p> <p><strong>Methods and results: </strong>We reanalysed 1075 cardiopulmonary exercise tests of HF patients recruited in the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score database. We identified DT in 43% of cases. Met AT precedes vent AT being met-ventΔVO<sub>2</sub> 221 (interquartile range: 129-319) mL/min. Peak VO<sub>2</sub> , 1307 ± 485 vs. 1343 ± 446 mL/min (63 ± 17 vs. 63 ± 17 percentage of predicted), was similar between DT+ and DT- patients. Differently, DT+ showed a lower ventilatory vs. carbon dioxide production (VE/VCO<sub>2</sub> ) slope (29.6 ± 6.1 vs. 31.0 ± 6.3), a lower peak exercise end-tidal oxygen tension (PetO<sub>2</sub> ) 115.3 (111.5-118.9) vs. 116.4 (112.4-120.2) mmHg, and a higher carbon dioxide tension (PetCO<sub>2</sub> ) 34.2 (30.9-37.1) vs. 32.4 (28.7-35.5) mmHg. Vent AT showed a significant higher VO<sub>2</sub> , 957 ± 318 vs. 719 ± 252 mL/min, VCO<sub>2</sub> , 939 ± 319 vs. 627 ± 226 mL/min, ventilation, 31.0 ± 8.3 vs. 22.5 ± 6.3 L/min, respiratory exchange ratio, 0.98 ± 0.08 vs. 0.87 ± 0.07, PetO<sub>2</sub> , 108 (104-112) vs. 105 (101-109) mmHg, PetCO<sub>2</sub> , 37 (34-40) vs. 36 (33-39) mmHg, and VE/VO<sub>2</sub> ratio, 33.5 ± 6.7 vs. 32.6 ± 6.9, but lower VE/VCO<sub>2</sub> ratio, 33 (30-37) vs. 36 (32-41), compared with met AT. At 2 year survival by Kaplan-Meier analysis, even adjusted for confounders, DT resulted not associated with survival.</p> <p><strong>Conclusions: </strong>Double threshold is frequently observed in HF patients. DT+ is associated to a decreased ventilatory response during exercise.</p> <p> </p>
Dataset related to the article: Salvioni E, Mapelli M, Bonomi A, Magri D, Piepoli M, Frigerio M, et al. Pick Your Threshold: A Comparison Among Different Methods of Anaerobic Threshold Evaluation in Heart Failure Prognostic Assessment. Chest. 2022;162:1106-1115.
<p><strong>Background: </strong>In clinical practice, anaerobic threshold (AT) is used to guide training and rehabilitation programs, to define risk of major thoracic or abdominal surgery, and to assess prognosis in heart failure (HF). AT of oxygen uptake (V.O<sub>2</sub>; V.O<sub>2</sub>AT) has been reported as an absolute value (V.O<sub>2</sub>ATabs), as a percentage of predicted peak V.O<sub>2</sub> (V.O<sub>2</sub>AT%peak_pred), or as a percentage of observed peak V.O<sub>2</sub> (V.O<sub>2</sub>AT%peak_obs). A direct comparison of the prognostic power among these different ways to report AT is missing.</p> <p><strong>Research question: </strong>What is the prognostic power of these different ways to report AT?</p> <p><strong>Study design and methods: </strong>In this observational cohort study, we screened data of 7,746 patients with HF with a history of reduced ejection fraction (< 40%) recruited between 1998 and 2020 and enrolled in the Metabolic Exercise Combined With Cardiac and Kidney Indexes register. All patients underwent a maximum cardiopulmonary exercise test, executed using a ramp protocol on an electronically braked cycle ergometer.</p> <p><strong>Results: </strong>This study considered 6,157 patients with HF with identified AT. Follow-up was median, 4.2 years (25th-75th percentiles, 1.9-5.0 years). Both V.O<sub>2</sub>ATabs (mean ± SD, 823 ± 305 mL/min) and V.O<sub>2</sub>AT%peak_pred (mean ± SD, 39.6 ± 13.9%), but not V.O<sub>2</sub>AT%peak_obs (mean ± SD, 69.2 ± 17.7%), well stratified the population regarding prognosis (composite end point: cardiovascular death, urgent heart transplant, or left ventricular assist device). Comparing area under the receiver operating characteristic curve (AUC) values, V.O<sub>2</sub>ATabs (0.680) and V.O<sub>2</sub>AT%peak_pred (0.688) performed similarly, whereas V.O<sub>2</sub>AT%peak_obs (0.538) was significantly weaker (P < .001). Moreover, the V.O<sub>2</sub>AT%peak_pred AUC value was the only one performing as well as the AUC based on peak V.O<sub>2</sub> (0.710), with an even a higher AUC (0.637 vs 0.618, respectively) in the group with severe HF (peak V.O<sub>2</sub> < 12 mL/min/kg). Finally, the combination of V.O<sub>2</sub>AT%peak_pred with peak V.O<sub>2</sub> and V. per CO<sub>2</sub> production shows the highest prognostic power.</p> <p><strong>Interpretation: </strong>In HF, V.O<sub>2</sub>AT%peak_pred is the best way to report V.O<sub>2</sub> at AT in relationship to prognosis, with a prognostic power comparable to that of peak V.O<sub>2</sub> and, remarkably, in patients with severe HF.</p>
Long-term results of surgical ventricular reconstruction and comparison with the Surgical Treatment for Ischemic Heart Failure trial
<p>Gaudino M, Castelvecchio S, Rahouma M, Robinson NB, Audisio K, Soletti GJ, Cancelli G, Tam DY, Garatti A, Benedetto U, Doenst T, Girardi LN, Michler RE, Fremes SE, Velazquez EJ, Menicanti L. Long-term results of surgical ventricular reconstruction and comparison with the Surgical Treatment for Ischemic Heart Failure trial. J Thorac Cardiovasc Surg. 2022 Apr 26:S0022-5223(22)00493-7. doi: 10.1016/j.jtcvs.2022.04.016. Epub ahead of print. PMID: 35599207.</p> <p><strong>Abstract</strong></p> <p><strong>Objective: </strong>The role of surgical ventricular reconstruction (SVR) in patients with ischemic cardiomyopathy is controversial. Observational series and the Surgical Treatment of IsChemic Heart failure (STICH) trial reported contradictory results. SVR is highly dependent on operator experience. The aim of this study is to compare the long-term results of SVR between a high-volume SVR institution and the STICH trial using individual patient data.</p> <p><strong>Methods: </strong>Patients undergoing SVR at San Donato Hospital (Milan) were compared with patients undergoing SVR in STICH (as-treated principle) by inverse probability treatment-weighted Cox regression. The primary outcome was all-cause mortality.</p> <p><strong>Results: </strong>The San Donato cohort included 725 patients, whereas the STICH cohort included 501. Compared with the STICH-SVR cohort, San Donato patients were older (66.0, lower quartile, upper quartile [Q1, Q3: 58.0, 72.0] vs 61.9 [Q1, Q3: 55.1, 68.8], P < .001) and with lower left ventricular end-systolic volume index at baseline (LVESVI: 77.0 [Q1, Q3: 59.0, 97.0] vs 80.8 [Q1, Q3: 58.5, 106.8], P = .02). Propensity score weighting yielded 2 similar cohorts. At 4-year follow-up, mortality was significantly lower in the San Donato cohort compared with the STICH-SVR cohort (adjusted hazard ratio, 0.71; 95% confidence interval, 0.53-0.95; P = .001). Greater postoperative LVESVI was independently associated with mortality (hazard ratio, 1.02; 95% confidence interval, 1.01-1.03). At 4 to 6 months of follow-up, the mean reduction of LVESVI in the San Donato cohort was 39.6%, versus 10.7% in the STICH-SVR cohort (P < .001).</p> <p><strong>Conclusions: </strong>Patients with postinfarction LV remodeling undergoing SVR at a high-volume SVR institution had better long-term results than those reported in the STICH trial, suggesting that a new trial testing the SVR hypothesis may be warranted.</p>
Heart Failure and Patient-Reported Outcomes in Adults With Congenital Heart Disease from 15 Countries
<p>Lu CW, Wang JK, Yang HL, Kovacs AH, Luyckx K, Ruperti-Repilado FJ, Van De Bruaene A, Enomoto J, Sluman MA, Jackson JL, Khairy P, Cook SC, Chidambarathanu S, Alday L, Oechslin E, Eriksen K, Dellborg M, Berghammer M, Johansson B, Mackie AS, Menahem S, Caruana M, Veldtman G, Soufi A, Fernandes SM, White K, Callus E, Kutty S, Apers S, Moons P; APPROACH‐IS consortium, the International Society for Adult Congenital Heart Disease (ISACHD) *. Heart Failure and Patient-Reported Outcomes in Adults With Congenital Heart Disease from 15 Countries. J Am Heart Assoc. 2022 May 3;11(9):e024993. doi: 10.1161/JAHA.121.024993. Epub 2022 Apr 26. PMID: 35470715; PMCID: PMC9238599.</p> <p>Abstract</p> <p>Background Heart failure (HF) is the leading cause of mortality and associated with significant morbidity in adults with congenital heart disease. We sought to assess the association between HF and patient-report outcomes in adults with congenital heart disease. Methods and Results As part of the APPROACH-IS (Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart disease-International Study), we collected data on HF status and patient-reported outcomes in 3959 patients from 15 countries across 5 continents. Patient-report outcomes were: perceived health status (12-item Short Form Health Survey), quality of life (Linear Analogue Scale and Satisfaction with Life Scale), sense of coherence-13, psychological distress (Hospital Anxiety and Depression Scale), and illness perception (Brief Illness Perception Questionnaire). In this sample, 137 (3.5%) had HF at the time of investigation, 298 (7.5%) had a history of HF, and 3524 (89.0%) had no current or past episode of HF. Patients with current or past HF were older and had a higher prevalence of complex congenital heart disease, arrhythmias, implantable cardioverter-defibrillators, other clinical comorbidities, and mood disorders than those who never had HF. Patients with HF had worse physical functioning, mental functioning, quality of life, satisfaction with life, sense of coherence, depressive symptoms, and illness perception scores. Magnitudes of differences were large for physical functioning and illness perception and moderate for mental functioning, quality of life, and depressive symptoms. Conclusions HF in adults with congenital heart disease is associated with poorer patient-reported outcomes, with large effect sizes for physical functioning and illness perception. Registration URL: https://clinicaltrials.gov; Unique identifier: <a href="http://clinicaltrials.gov/show/NCT02150603">NCT02150603</a>.</p>
Prognostic value of left atrial strain quantification from 2D ultrasound imaging in post-ischemic heart failure patients: evidence from the REMODEL-HF study.
<p>Frigelli M, Sturla F, Milani V, Ramputi L, Citarella M, Menicanti L, Votta E, Castelvecchio S. Prognostic value of left atrial strain quantification from 2D ultrasound imaging in post-ischemic heart failure patients: evidence from the REMODEL-HF study. Int J Cardiol. 2022 Sep 1;362:183-189. doi: 10.1016/j.ijcard.2022.04.071. Epub 2022 Apr 30. PMID: 35504452.</p> <p>Abstract</p> <p><strong>Background: </strong>Left atrial (LA) function can be effectively assessed by measuring longitudinal LA strain (LAS) via two-dimensional speckle tracking echocardiography (2DSTE). Here, we test 2DSTE-based LAS as marker of different left ventricle (LV) remodeling patterns and as prognostic index in ischemic heart failure (HF) candidates to surgical ventricular reconstruction.</p> <p><strong>Methods: </strong>We retrospectively considered ischemic HF patients with anterior (group A, n=130) or posterior (group P, n=48) LV remodeling. Based on 2D ultrasound, LV and LA morpho-functional parameters were quantified including reservoir (LAS<sub>Res</sub>), conduit (LAS<sub>Cond</sub>) and booster (LAS<sub>Boost</sub>) LAS. We tested their capability to discriminate between groups A and P, and their group-specific prognostic significance for the composite end-point of death or HF re-hospitalization at follow-up (mean follow-up time=40 months, range 3-101 months).</p> <p><strong>Results: </strong>Group A and group P displayed similar end-diastolic (p=0.89) and end-systolic (p=0.33) LV volume index, and LA volume index LAVi (p=0.44) corrected for the degree of mitral regurgitation. As compared to group P, group A revealed a significant reduction in LAS<sub>Boost</sub> (9.2±0.4% vs. 11.1±0.7%, p=0.04) and a non-significant reduction in LAS<sub>Res</sub> (16.9±0.7% vs. 19.3±1.1%, p=0.06). Kaplan-Meier curves showed that the median LAS<sub>Res</sub> and LAS<sub>Boost</sub> values effectively stratified patients based on their prognosis in the overall study population (Log-rank p=0.002 and Log_rank p<0.0001) and in group A, where the association was stronger for LAS<sub>Boost</sub> (Log-rank p<0.001) than for LAS<sub>Res</sub> (Log-rank p=0.013).</p> <p><strong>Conclusions: </strong>2DSTE-based LAS assessment is affordable, repeatable and non-invasive, and could add clinically-relevant mechanistic insight and prognostic value in the stratification of ischemic HF patients.</p>
Raw data for "Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. Eur J Clin Pharmacol. 2023;79:1173-1184." and "Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways;Drugs R D. 2023 Sep 13. doi: 10.1007/s40268-023-00438-2."
<p><strong>Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways:</strong></p> <p><strong>Background and objective: </strong>N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble interleukin 1 receptor-like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severity. Both are potential targets of HFrEF treatment, but the first is associated with the patient's hemodynamic status, while the second is more indicative of the inflammatory status and of myocardial fibrosis. The aim of this study was to assess the kinetics of these biomarkers after treatment with sacubitril/valsartan in HFrEF.</p> <p><strong>Methods: </strong>We analyzed blood samples of patients with HFrEF at baseline (before sacubitril/valsartan treatment), after 1, 2, and 3 months (respectively, after a month taking the 24/26 - 49/51 - 97/103 mg twice daily, or b.i.d., doses), and 6 months after the maximum-tolerated dose was reached (end study).</p> <p><strong>Results: </strong>We obtained samples from 72 patients with HFrEF (age 64.0 ± 10.5 years, 83% males). NT-proBNP and sST2 values progressively and significantly reduced to 37% and 16%, respectively, with a greater reduction for NT-proBNP (p < 0.001). Specifically, NT-proBNP reduced from 1144 [593-2586] pg/mL to 743 [358-1524] pg/mL and sST2 from 27.3 [20.5-35.0] ng/mL to 23.1 [15.9-30.7] ng/mL, p for trend < 0.001 in both cases. The reduction of the two biomarkers over time occurred with statistically significant different kinetics: deferred for sST2 and faster for NT-proBNP. No significant changes in renal function and potassium levels were recorded.</p> <p><strong>Conclusion: </strong>These findings suggest that, in patients with HF, sacubitril/valsartan effects on the cardiovascular system share a double pathway: a first, hemodynamic, faster pathway and a second, non-hemodynamic anti-fibrotic, delayed one. Both likely contribute to the sacubitril/valsartan benefits in HFrEF.</p> <p> </p> <p><strong>Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration</strong></p> <p><strong>Purpose: </strong>Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting results. Aim of our study was to evaluate the impact of sacubitril/valsartan on exercise parameters and echocardiographic and biomarker changes at different drug doses.</p> <p><strong>Methods: </strong>We prospectively enrolled consecutive HFrEF outpatients eligible to start sacubitril/valsartan. Patients underwent clinical assessment, cardiopulmonary exercise test (CPET), blood sampling, echocardiography, and completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Sacubitril/valsartan was introduced at 24/26 mg b.i.d. dose and progressively uptitrated in a standard monthly-based fashion to 97/103 mg b.i.d. or maximum tolerated dose. Study procedures were repeated at each titration visit and 6 months after reaching the maximum tolerated dose.</p> <p><strong>Results: </strong>Ninety-six patients completed the study, 73 (75%) reached maximum sacubitril/valsartan dose. We observed a significant improvement in functional capacity across all study steps: oxygen intake increased, at peak exercise (from 15.6 ± 4.5 to 16.5 ± 4.9 mL/min/kg; p trend = 0.001), while minute ventilation/carbon dioxide production relationship reduced in patients with an abnormal value at baseline. Sacubitril/valsartan induced positive left ventricle reverse remodeling (EF from 31 ± 5 to 37 ± 8%; p trend < 0.001), while NT-proBNP reduced from 1179 [610-2757] to 780 [372-1344] pg/ml (p trend < 0.0001). NYHA functional class and the subjective perception of limitation in daily life at KCCQ-12 significantly improved. The Metabolic Exercise Cardiac Kidney Index (MECKI) score progressively improved from 4.35 [2.42-7.71] to 2.35% [1.24-4.96], p = 0.003.</p> <p><strong>Conclusions: </strong>A holistic and progressive HF improvement was observed with sacubitril/valsartan in parallel with quality of life. Likewise, a prognostic enhancement was observed.</p>
Raw data for "The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database" 2023 Int J Cardiol
<p>Abstract</p> <p><strong>Background: </strong>The role of risk scores in heart failure (HF) management has been highlighted by international guidelines. In contrast with HF, which is intrinsically a dynamic and unstable syndrome, all its prognostic studies have been based on a single evaluation. We investigated whether time-related changes of a well-recognized risk score, the MECKI score, added prognostic value. MECKI score is based on peak VO<sub>2</sub>, VE/VCO<sub>2</sub> slope, Na<sup>+</sup>, LVEF, MDRD and Hb.</p> <p><strong>Methods: </strong>A multi-centre retrospective study was conducted involving 660 patients who performed MECKI re-evaluation at least 6 months apart. Based on the difference between II and I evaluation of MECKI values (MECKI II - MECKI I = ∆ MECKI) the study population was divided in 2 groups: those presenting a score reduction (∆ MECKI <0, i.e. clinical improvement), vs. patients presenting an increase (∆ MECKI >0, clinical deterioration).</p> <p><strong>Results: </strong>The prognostic value of MECKI score is confirmed also when re-assessed during follow-up. The group with improved MECKI (366 patients) showed a better prognosis compared to patients with worsened MECKI (294 patients) (p < 0.0001). At 1st evaluation, the two groups differentiated by LVEF, V<sub>E</sub>/VCO<sub>2</sub> slope and blood Na<sup>+</sup> concentration, while at 2nd evaluation they differentiated in all 6 parameters considered in the score. The patients who improved MECKI score, improved in all components of the score but hemoglobin, while patients who worsened the score, worsened all parameters.</p> <p><strong>Conclusions: </strong>This study shows that re-assessment of MECKI score identifies HF subjects at higher risk and that score improvement or deterioration regards several MECKI score generating parameters confirming the holistic background of HF.</p>
Chromatin Remodeling Drives Immune-Fibroblast Cell Communication in Heart Failure (ChIP-Seq)
GEO Series GSE221694. Homo sapiens. 6 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Chromatin Remodeling Drives Immune-Fibroblast Cell Communication in Heart Failure (Cut & Run)
GEO Series GSE221695. Mus musculus. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Pannexin 1 Channels Control Cardiomyocyte Metabolism and Neutrophil Recruitment During Non-Ischemic Heart Failure
GEO Series GSE267693. Mus musculus. 23 samples. Type: Expression profiling by high throughput sequencing.
Comprehensive analysis of the RNA transcriptome expression profiles and construction of the ceRNA network in heart failure patients
GEO Series GSE212181. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
An inflammatory single-cell RNA sequencing signature driven by metabolic stress in a new mouse model of heart failure with preserved ejection fraction and its reversion by the SGLT2 inhibitor dapaglif
GEO Series GSE209548. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Chromatin Remodeling Drives Immune-Fibroblast Cell Communication in Heart Failure (scATAC-Seq)
GEO Series GSE221696. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
Different expression of inflammation-related proteins in human heart failure
GEO Series GSE86569. Homo sapiens. 22 samples. Type: Expression profiling by array.
RNA-sequencing of epicardial adipose tissue of heart failure patients with preserved ejection fraction
GEO Series GSE192886. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
Defining cardiac functional recovery in end-stage heart failure at single cell resolution
GEO Series GSE226314. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
Impaired Branched-Chain Amino Acid Catabolism is Associated with Chemotherapy-Induced Heart Failure and Rescued by Metformin
GEO Series GSE230638. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.